The India Resurgence Fund, run by global investment firm Bain Capital Credit and the Piramal Enterprises Ltd. conglomerate, has unveiled a rescue package worth up to $144m (INR9.92bn) for debt-laden Indian vaccines maker Panacea Biotec Ltd., which has been struggling to get back on its financial feet for nearly a decade.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?